

# Genomic Sequence, Organization, and Chromosomal Localization of Human JAK3

M. C. RIEDY,<sup>\*1</sup> AMALIA S. DUTRA,<sup>†</sup> TREVOR B. BLAKE,<sup>†</sup> WILLIAM MODI,<sup>‡</sup> B. K. LAL,<sup>\*</sup>  
JONATHAN DAVIS,<sup>\*</sup> ANGELIQUE BOSSE,<sup>\*</sup> JOHN J. O'SHEA,<sup>\*</sup> AND JAMES A. JOHNSTON<sup>\*</sup>

<sup>\*</sup>Lymphocyte Cell Biology Section, Arthritis and Rheumatism Branch, NIAMS and <sup>†</sup>NCHGR National Institutes of Health, Bethesda, Maryland 20892, <sup>‡</sup>ABL NCI-FCRDC, Frederick, Maryland 21702-1201

Received January 2, 1996; accepted June 20, 1996

Members of the Janus (JAK) protein tyrosine kinase family including JAK3 have recently emerged as important components in cytokine signal transduction. Mutations of JAK3 have been found in a number of patients who present with severe combined immunodeficiency. To facilitate the further identification of JAK3-SCID patients and to understand the structure of JAK3 better, we undertook the determination of the genomic sequence, organization, and chromosomal localization of the *JAK3* gene. The *JAK3* gene was found to consist of 19 exons and 18 introns. Interestingly, the organization of the kinase-(JH1) and pseudokinase-(JH2) domains were found to be dissimilar. In addition, the *JAK3* gene was localized to human chromosome 19p13.1. These data should facilitate the identification of patients with this new form of immunodeficiency and will provide insight into the structure of this kinase. © 1996 Academic Press, Inc.

## INTRODUCTION

Cytokines and hormones that bind to members of the hematopoietic cytokine receptor superfamily (Bazan, 1990) have critical functions in regulating the growth and differentiation of a variety of cells. Cytokine receptors lack intrinsic kinase domains but nonetheless, ligand binding induces the rapid tyrosine phosphorylation of a variety of intracellular substrates (Taniguchi, 1995; Ihle *et al.*, 1994). Members of the Janus family (JAK) of protein tyrosine kinases (PTKs) have emerged as key elements in the signal transduction mechanism of cytokine receptors (Velazquez *et al.*, 1992).

There are four mammalian JAKs. In contrast to JAK1, JAK2, and Tyk2, which have ubiquitous tissue expression, JAK3 is preferentially expressed in hematopoietic cells (Kawamura *et al.*, 1994). It is activated

Sequence data from this article have been deposited with the EMBL/GenBank Data Libraries under Accession No. U70065.

<sup>1</sup>To whom correspondence should be addressed. Telephone: (301) 496-2541. Fax: (301) 402-0012. E-mail: RiedyM@arb.niams.nih.gov.

in response to IL-2 and related cytokines (Johnston *et al.*, 1994, Tortolani *et al.*, 1995; Musso *et al.*, 1995, Witthuhn *et al.*, 1994). JAK3 binds to  $\gamma c$ , a subunit that is a component of the receptors for a number of cytokines including IL2, IL4, IL7, IL9, and IL15 (Johnston *et al.*, 1995; Russell *et al.*, 1994). Consequently, JAK3 is activated by these cytokines.

Mutations of  $\gamma c$  have been shown to result in X-linked severe combined immunodeficiency (X-SCID) (Noguchi *et al.*, 1993; Leonard *et al.*, 1994; Tassara *et al.*, 1995). The intimate association of JAK3 and  $\gamma c$  led to the search for patients with immunodeficiency due to mutations of JAK3. The identification of such patients has recently been reported (Macchi *et al.*, 1995; Russell *et al.*, 1995). Like X-SCID patients, patients with JAK3 deficiency also presented with persistent severe infections in early life and were found to lack T and NK cells. Although B cells were present, the patients have hypoglobulinemia. These findings underscore the requirement for JAK3 in the proper development and function of the immune system.

In view of its fundamental role in this form of immunodeficiency and to facilitate the identification of additional patients, it was important to define the genomic sequence and chromosomal localization of JAK3. We report here the complete genomic sequence of the *JAK3* gene and show that it comprises 19 exons and 18 introns. Additionally, we localized the *JAK3* gene to chromosome 19p13.1.

## MATERIALS AND METHODS

**Genomic cloning.** Charon 4A human genomic  $\lambda$  phage library was obtained from Dr. T. Maniatis (Harvard Medical School). Briefly, 5  $\times$  10<sup>5</sup> PFU of phage were plated and duplicate filters were probed with a <sup>32</sup>P-labeled PCR product from the 5' end of JAK3 cDNA corresponding to the JH3–JH7 domains. Three positive clones were identified.  $\lambda$  phage were grown and purified by standard methods (Sambrook *et al.*, 1989). In addition, P1 plasmids were obtained from Genome Systems (St. Louis, MO) using the following primer pairs corresponding to the JAK3 cDNA: forward primer, 5'CAGCACCA-AGTCCTGCT3' (JAK3 bases 374–391); reverse primer, 5'TGGGAG-AGGAACCTCTGACT3' (JAK3 bases 556–575). Three clones were

provided. The P1 clones were grown and purified following the protocol recommended by Genome Systems. Cellular genomic DNA was extracted using Easy-DNA Kit (Invitrogen, San Diego, CA).

**Sequencing of the JAK3 gene.** Primers were constructed approximately every 200 bases from the published sequence of the JAK3 cDNA (GenBank Accession No. HSU09607). To amplify DNA fragments from a genomic template, 200 ng of template DNA (purified  $\lambda$  phage, P1 plasmid genomic DNA, or human T-cell DNA) was added to 10 $\times$  PCR buffer (Boehringer-Mannheim, Indianapolis, IN), 2.5 U *Taq* polymerase (Boehringer-Mannheim), 1 mM dNTP (Boehringer-Mannheim), 10 pmol each primer, and nuclease-free ddH<sub>2</sub>O to make a final volume of 100  $\mu$ l. The reaction was cycled 30 times. The PCR products were electrophoresed on a horizontal 0.8% agarose gel containing 0.5  $\mu$ g/ml ethidium bromide.

PCR products were purified using the QIAquick Gel Extraction Kit (Qiagen Inc., Chatsworth, CA) or the QIAquick PCR Purification Kit. Purified PCR fragments (100 ng) and 10 pmol of individual primers were added to the ABI PRISM DyeDeoxy Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer, Foster City, CA). The reaction was subjected to 25 cycles. Products were analyzed on the ABI PRISM 373A DNA Sequencer and compiled using GCG software (Genetics Computer Group, Inc., Madison, WI). The fragments were aligned based upon the cDNA sequence of human JAK3, and intron-exon boundaries followed the AG/GT rule (Mount, 1982). Sequencing of both strands was performed to verify the results. Discrepancies were then resolved by resequencing the region in question using P1 plasmid,  $\lambda$  phage, and human T-cell DNA.

**Chromosomal localization.** Chromosome preparations were made from BrdU-treated human peripheral blood cultures as described by Hirai and colleagues (Hirai *et al.*, 1994).  $\lambda$  Phage DNA from two JAK3 genomic clones was labeled with digoxigenin-11-dUTP (Boehringer Mannheim, Germany) by nick-translation (Boehringer Mannheim). This probe was visualized using an anti-digoxigenin labeled with rhodamine. A second probe corresponding to an  $\alpha$ -satellite DNA unique to human chromosome 19 was prepared from a human monochromosomal hybrid using PCR to incorporate biotinylated nucleotides (Weier *et al.*, 1991). The chromosome 19 probe was visualized using FITC-labeled avidin. Hybridization was performed and DAPI, a DNA dye, was used as a counterstain as described by Hirai *et al.* (1994). Twenty metaphase spreads were viewed with a Zeiss Axiophot microscope equipped with a triple band-pass filter to detect signals simultaneously. Images were collected and merged using a CCD camera (KAF 1400, Photometrics, Tucson, AZ) and IPLab Spectrum software (Signal Analytics Vienna, VA).

## RESULTS

**Genomic sequencing.** To determine the sequence and structure of the JAK3 gene, clones were isolated from human genomic  $\lambda$  phage (Charon 4A) and P1 plasmid libraries. Primers were derived from the JAK3 cDNA sequence or were synthesized to traverse intronic sequence as required. The JAK3 genomic sequence comprises approximately 13,600 bp, which corresponds to 19 exons and 18 introns. All of the exon-intron splice junctions agree with the GT/AG rule (Mount, 1982), and Table 1 outlines these junctions. The first 200 bases define a portion of the 5' untranslated region and the most 3' exon (exon 19) also contains untranslated sequence. Figure 1 is a schematic representation of the JAK3 gene and the exon-intron usage as it relates to the encoded protein. The locations of the various JAK homology (JH) domains are shown. The catalytic domain of JAK3 and other Janus kinases is the JH1 domain, which is encoded by exons 16–19. The pseudokinase domain, JH2, is encoded by exons 9–15.

**Chromosomal localization.** Using fluorescence *in situ* hybridization on PHA-activated peripheral blood leukocytes, a total of 20 metaphase cells were examined after hybridization with two genomic JAK3 probes. All 20 of the cells revealed paired hybridization signals (JAK3 and the chromosome 19  $\alpha$ -satellite) with a strong signal at chromosome 19p13.1 (Fig. 2A). No significant background was noted at any other chromosomal locations with the probes. The chromosomal localization of JAK3 was verified by specific amplification of human JAK3 from a panel of rodent/human hybrid cells (Coriell Cell Repositories, Camden, NJ), which contain specific human chromosomes. JAK3 fragments were amplified, in three separate experiments, from cellular DNA obtained from cells containing human chromosome 19 and not from those cells containing other human chromosomes (data not shown). Rodent JAK3 was not amplified from these cells with the primer pairs utilized.

Figure 2B illustrates an ideogram of human chromosome 19 depicting the localization of JAK3 to p13.1. Interestingly, the JAK3 locus is in proximity to another Janus kinase, Tyk2 (19p13.2) (Frimbach-Kraft *et al.*, 1990). In addition, the erythropoietin receptor and the proto-oncogene Vav (Ropers and Pericak-Vance, 1991) also map to 19p13.2. Interestingly, another PTK, Chk, which is expressed at high levels in NK cells, also maps to chromosome 19 (Authors' unpublished observations).

## DISCUSSION

The importance of JAK3 in cytokine signal transduction and in lymphoid development has been emphasized by the recent finding that diverse mutations in this gene result in severe combined immunodeficiency in humans (Russell *et al.*, 1995; Macchi *et al.*, 1995). These patients lack T cells and have greatly reduced B-cell numbers. The complete sequence of the JAK3 gene should facilitate the identification of new patients with JAK3 deficiency.

The mapping of JAK3 to human chromosome 19p13.1 is interesting in that the closely related family member Tyk2 is also localized to chromosome 19 at band p13.2 (Frimbach-Kraft *et al.*, 1990). In contrast, the gene encoding human JAK1 has been localized to chromosome 1 (p31.3), and JAK2, the family member with the greatest homology to JAK3, has been provisionally localized to human chromosome 9 (p24) (Pritchard *et al.*, 1992). Although these kinases share considerable structural homology at the protein level, the finding that they reside upon three separate chromosomes suggests that the genes most likely result from distant evolutionary duplication.

Many of the genes that encode PTKs appear to have arisen by repeated gene duplication of a common ancestor. An excellent example of this is *c-src*, and the related family members *fgr*, *Ick*, *Lyn*, and *yes*, which share

TABLE 1  
Exon–Intron Boundaries of the *JAK3* Gene

Exon (donor site)	Intron	Exon (acceptor site)
1 GCCAAGGCCAGCG	gtgagtgcatc . . . tccccctgttag	2 GCATCCTGCCTGTG
2 CTGTACAGGATTGCG	gttcgacaggaa . . . tctcttcacag	3 CTTTACTTCCCCAA
3 ACCTCTTGCCAG	gtggggttctg . . . ggccccccag	4 CACCGCATTGACCT
4 CTGAAGACTGTCAG	gtgagagccac . . . cccctcgag	5 CTACAAGGCTGCCT
5 CCAGGGAGAACAGG	gtgaggacggaa . . . acaacccag	6 TCCTCCAGCCCTTC
6 CAACCAAGATTTAG	gtgggtgcagg . . . gtccctcgag	7 GAGGCCGAGTTCCC
7 CTGTCTGTGTCAG	gtcgggttact . . . acttcttgg	8 AACCCCTTGGTCC
8 CCCCAGACCCAAAG	gtgaggcccc . . . ctctccccatag	9 AAAAGTCCAACCTG
9 ACAGCCTGGAGTGG	gtaagaggcc . . . tcaccattcag	10 CATGAGAACCTGG
10 AGAACTGCATGGAG	gtgagggtgg . . . accttccccag	11 TCATTCTGGAAAGC
11 TGGCTGGAGACAG	gtgagtgctcc . . . tatggctgag	12 CACCATGGTGCAGG
12 CCCTCAACTATCTG	gtgagtgctct . . . ggcccccttag	13 GAGGACAAAGGCCT
13 TGTTAACGCTGGAG	gtaagtcttcc . . . tcattcccttag	14 ATGCTCACCGACAG
14 TGGATCCTGCTAAG	gtcagagcccc . . . tcaccctcag	15 AAACCTCCAATTTTAT
15 CCTCATCTCTTCAG	gtgcccgctgg . . . ccaccccg	16 ACTATGAGCTCCTC
16 ACAGCTGGGCAAG	gtaagggtggc . . . ctatcctegag	17 GGCAACTTTGGCAG
17 AGCTATGGCCCGG	gtgagccagct . . . tgccttccag	18 GCCGGCCAGACCT
18 GCAGATCTGCAAG	gtgagagggg . . . cccccccag	19 GGCATGGAGTACCT
		. . . CCTGTCCTTTCATAG

closely related nucleotide sequences and substantial exon–intron organization (Yasmanashi *et al.*, 1987). When other JAK family genomic sequences are reported, comparisons can be made between the Janus family members as to similarities in exon–intron usage, thus determining whether they share a common ancestry.

It has been suggested that the JH2 domain arose by duplication of the JH1 domain. If this were the case, it might be expected that the exon structure of the JH2 domain would be roughly equivalent to that of the JH1 domain. Interestingly, this is not the case. This lack of similarity may suggest that the JH1 and JH2 domains arose from different ancestral genes.

Many PTKs have been described as oncogenes that are involved in critical cellular signaling events. Dur-

ing transformation, there can be a dysregulated expression or function of these kinases. It is of interest, therefore, that JAK3 maps in proximity to loci involved in acute myelogenous leukemia and B-cell lymphoma (Ropers and Pericak-Vance, 1991; Mitelman *et al.*, 1991; Kaneko *et al.*, 1989). Interestingly, JAK3 is expressed at high levels in bone marrow aspirates from patients with B-cell ALL and in cell lines derived from patients with B-cell lymphomas (Tortolani *et al.*, 1995). Importantly, it has been demonstrated that mutations of a JAK can result in leukemia in *Drosophila* (Harrison *et al.*, 1995, Binari and Perrimon, 1994). Constitutive activation of the JAK3 pathway has been shown in HTLV1 (Migone *et al.*, 1995) and *v-abl* transformed cells. It will be important to determine if the *JAK3* gene is disrupted in any of these hematologic malignan-




FIG. 1. Genomic organization and comparison to putative domains of JAK3 protein. The exons and introns encoding the various Janus homology (JH) domains are indicated.




FIG. 2. (A) Human metaphase spread showing the specific site of hybridization to chromosome 19. The arrow pointing to the green band highlights *JAK3* at 19p13.1. Chromosome identification was carried out using an  $\alpha$ -satellite probe (red). (B) Idiogram of human chromosome 19 (Ashworth *et al.*, 1995). Localization of other genes within close proximity of *JAK3* is illustrated.

cies and to determine if *JAK3* contributes to transformation. Additionally, it was reported by Lai and colleagues that there are variant forms of *JAK3* found in breast carcinoma cell lines and in a chronic myelogenous leukemic cell line (Lai *et al.*, 1995). Surprisingly, the exon–intron structure of *JAK3* does not explain the genesis of such altered forms of the *JAK3* protein.

In summary, this report assigns the locus of *JAK3*—autosomal SCID to human chromosome 19p13.1. The knowledge of the gene structure will help to identify new patients and to develop therapeutic approaches aimed at this gene.

#### ACKNOWLEDGMENTS

We thank George Poy for his expertise in automated sequencing and synthesizing oligonucleotide primers. We thank Drs. Allan Weissman, Jeff Trent, and Warren Leonard for reading the manuscript and providing helpful suggestions and Jennifer Puck for her helpful advice.

*Note added in proof.* The murine *JAK3* gene has been localized to chromosome 8 (Kono *et al.*, 1996). Other murine homologues of human genes expressed on human chromosome 19p13.1 also map to chromosome 8, suggesting that these regions are indeed syntenic.

#### REFERENCES

- Ashworth, L. K., Batzer, M. A., Brandrif, B., Branscomb, E., de Jong, P., Garcia, E., Garner, J. A., Garnes, A. G., Gordon, L. A., Lamerdin, J. E., Lennon, G., Mohrenweiser, H., Olsen, A. S., Slezak, T., and Caarrano, A. V. (1995). An integrated metric physical map of human chromosome 19. *Nature Genet.* 11: 422–427.
- Bazan, J. F. (1990). Structural design and molecular evolution of a cytokine receptor superfamily. *Proc. Natl. Acad. Sci. USA* 87: 6934–6938.
- Binari, R., and Perrimon (1994). Stipe-specific regulation of pair-rule genes by hopscotch, a putative JAK family tyrosine kinase in *Drosophila*. *Genes Dev.* 8: 300–312.
- Frimbach-Kraft, I., Byers, M., Shows, T., Dalla-Favera, R., and Kroleski, J. J. (1990). Tyk2, prototype of novel class of non-receptor tyrosine kinase gene. *Oncogene* 5: 1329–1336.
- Harrison, D. A., Binari, R., Nahreini, T. S., Gilman, M., and Perrimon, N. (1995). Activation of a *Drosophila* Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. *EMBO J.* 14: 2857–2865.
- Hirai, M., Suto, Y., and Kanoh, M. (1994). A method for simultaneous detection of fluorescent G-bands and *in situ* hybridization signals. *Cytogenet. Cell Genet.* 66: 149–151.
- Ihle, J. N., and Kerr, I. M. (1995). JAKs and STATs in signaling by the cytokine receptor superfamily. *Trends Genet.* 11: 69–74.
- Ihle, J. N., Witthuhn, B. A., Quelle, F. W., Yamamoto, K., Thierfelder,

- W. E., Kreider, B., and Silvennoinen, O. (1994). Signaling by the cytokine receptor superfamily: JAKs and STATs. *Trends Biochem. Sci.* 19: 222–226.
- Johnston, J. A., Kawamura, M., Kirken, R. A., Chen, Y. Q., Blake, T. B., Shibuya, K., Ortaldo, J. R., McVicar, D. W., and O'Shea, J. J. (1994). Phosphorylation and activation of the JAK3 Janus kinase in response to IL-2. *Nature* 370: 151–153.
- Johnston, J. A., Bacon, C. M., Finbloom, D. S., Rees, R. C., Kaplan, D., Shibuya, K., Ortaldo, J. R., Gupta, S., Chen, Y.-Q., Giri, J. D., and O'Shea, J. J. (1995). Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. *Proc. Natl. Acad. Sci. USA* 92: 5705–5709.
- Kaneko, Y., Frizzera, G., Shikano, T., Kobayashi, H., Maseki, N., and Skurai, M. (1989). Chromosomal and immunophenotypic patterns in T cell acute lymphoblastic leukemia (T ALL) and lymphoblastic lymphoma (LBL). *Leukemia* 3: 886–892.
- Kawamura, M., McVicar, D. W., Johnston, J. A., Blake, T. B., Chen, Y. Q., Lal, B. K., Lloyd, A. R., Kelvin, D. J., Staples, J. E., Ortaldo, J. R., and O'Shea, J. J. (1994). Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. *Proc. Natl. Acad. Sci. USA* 91: 6374–6378.
- Kono, D. H., Owens, D. G., and Wechsler, A. R. (1996). JAK3 maps to chromosome 8. *Mamm. Genome* 7: 476–477.
- Lai, K. S., Jin, Y., Graham, D. K., Witthuhn, B. A., Ihle, J. N., and Liu, E. T. (1995). A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. *J. Biol. Chem.* 270: 25028–25036.
- Leonard, W. J., Noguchi, M., Russell, S. M., and McBride, O. W. (1994). The molecular basis of X-linked severe combined immunodeficiency: The role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. *Immunol. Rev.* 138: 61–86.
- Macchi, P., Villa, A., Gilliani, S., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G., Johnston, J. A., Candotti, F., O'Shea, J. J., Vezzoni, P., and Notarangelo, L. D. (1995). Mutations of JAK3 gene in patients with autosomal severe combined immune deficiency (SCID). *Nature* 377: 65–68.
- Migone, T.-S., Lin, J. X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., and Leonard, W. J. (1995). Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1. *Science* 269: 79–81.
- Mitelman, R., Kaneko, Y., and Trent, J. (1991). Report of the committee on chromosome changes in neoplasia. *Cytogenet. Cell Genet.* 58: 1053–1079.
- Mount, S. M. (1982). A catalogue of splice junction sequences. *Nucleic Acids Res.* 10: 459–472.
- Musso, T., Johnston, J. A., Linnekin, D., Varesio, L., Rowe, R. K., O'Shea, J. J., and McVicar, D. W. (1995). Regulation of JAK3 expression in human monocytes: Phosphorylation in response to interleukins 2, 4, and 7. *J. Exp. Med.* 181: 1425–1431.
- Noguchi, M., Yi, H., Rosenblatt, H. M., Filipovich, A. H., Adelsteen, S., Modi, W. S., MicPoride, O. W., and Leonard, W. J. (1993). Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. *Cell* 73: 147.
- Pritchard, M. A., Baker, E., Callen, D. F., Sutherland, G. R., and Wilks, A. F. (1992). Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24. *Mamm. Genomics* 3: 36–38.
- Ropers, H. H., and Pericak-Vance, M. A. (1991). Report of the committee on the genetic constitution of chromosome 19. *Cytogenet. Cell Genet.* 58: 751–784.
- Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., O'Shea, J. J., and Leonard, W. J. (1995). Mutation of JAK3 in a patient with SCID: Essential role of JAK3 in lymphoid development. *Science* 270: 797–799.
- Russell, S. M., Johnston, J. A., Noguchi, M., Kawamura, M., Bacon, C. M., Friedmann, M., Berg, M., Witthuhn, B. A., Goldman, A. S., Schmalsteig, F. C., Ihle, J. N., O'Shea, J. J., and Leonard, W. J. (1994). Interaction of IL-2R $\beta$  and  $\gamma_c$  chains with JAK1 and JAK3 implications for XSCID and SCID. *Science* 266: 1042–1045.
- Sambrook, J., Fritsch, E., and Maniatis, T. (1989). In "Molecular Cloning: A Laboratory Manual," 2nd ed., pp. 2.73–2.81, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
- Taniguchi, T. A. (1995). Cytokine signaling through nonreceptor protein tyrosine kinases. *Science* 268: 251–255.
- Tassara, C., Pepper, A. E., and Puck, J. M. (1995). Intronic point mutation in the IL2R $\gamma$  gene causing X-linked severe combined immunodeficiency. *Hum. Mol. Genet.* 4: 1693–1695.
- Tortolani, P. J., Lal, B. K., Riva, A., Johnston, J. A., Chen, Y.-Q., Reaman, G. H., Beckwith, M., Longo, D., Ortaldo, J. R., Bhatia, K., McGrath, I., Kehrl, J., Tuscano, J., McVicar, D. W., and O'Shea, J. J. (1995). Regulation of JAK3 expression and activation in human B cells and B cell malignancies. *J. Immunol.* 155: 5220–5226.
- Velazquez, L., Fellous, M., Stark, G. R., and Pellegrini, S. (1992). A protein tyrosine kinase in the interferon  $\alpha/\beta$  signalling pathway. *Cell* 70: 313–322.
- Weier, H. U., Lucas, J. N., Poggensee, M., Segravees, R., Pinkel, D., and Gray, J. W. (1991). Two-color hybridization with high complexity chromosome-specific probes and a degenerate alpha satellite probe DNA allows unambiguous discrimination between symmetrical and asymmetrical translocations. *Chromosoma* 100: 371–376.
- Witthuhn, B. A., Silvennoinen, O., Miura, O., Lai, K. S., Cwik, C., Liu, E. T., and Ihle, J. N. (1994). Involvement of the JAK-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. *Nature* 370: 153–157.
- Yasmanashi, Y., Fukushima, S.-I., Semb, K., Sukegawa, J., Miyajima, N., Matsubara, K.-I., Yamamoto, T., and Toyoshima, K. (1987). The Yes-related cellular gene Lyn encodes a possible tyrosine kinase similar to p56 Lck. *Mol. Cell. Biol.* 7: 237–243.